NL-OMON37098
已完成
4 期
Prospective, pharmacokinetic study for determination of the relationship between lean body weight and anti-Xa activity 4 hours after subcutaneous administration of 5700 IU nadroparin in morbidly obese patients after bariatric surgery. - Nadroparin and anti-Xa activity after bariatric surgery
Rijnstate Ziekenhuis0 个研究点目标入组 50 人待定
概览
- 阶段
- 4 期
- 干预措施
- 未指定
- 疾病 / 适应症
- antistolling profylaxe bij bariatrische chirurgie
- 发起方
- Rijnstate Ziekenhuis
- 入组人数
- 50
- 状态
- 已完成
- 最后更新
- 2年前
概览
简要总结
暂无简介。
研究者
入排标准
入选标准
- •approval for Roux\-en\-Y gastric bypass
- •body weight of \> 140 kg
排除标准
- •renal impairment (GFR \< 30 and/or serum creatinin \> 150\)
- •Anticoagulation disorders (PT/APT \> 2x norm)
- •Use of oral anticoagulation (such as acenocoumarol)
结局指标
主要结局
未指定
相似试验
进行中（未招募）
不适用
Profylaxis of venous thromboembolism after bariatric surgery.patientsperioperative in bariatric surgeryTherapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04]EUCTR2012-002816-19-NLRijnstate Hospital
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.Rheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2012-000535-36-CZAbbott GmbH & Co. KG100
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.Rheumatoid ArthritisMedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Musculoskeletal Diseases [C05]EUCTR2012-000535-36-DEAbbVie Deutschland GmbH & Co. KG100
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.EUCTR2012-000535-36-PLAbbott GmbH & Co. KG100
已完成
不适用
Clinical study to investigate the pharmacokinetics, efficacy, safety and immunogenicity of human-cl rhFVIII in previously treated patients with severe haemophilia ASevere haemophilia AHaematological DisordersHereditary factor VIII deficiencyISRCTN87293301Octapharma AG (Switzerland)20